Published in Am J Gastroenterol on July 10, 2012
Long-Term Proton Pump Inhibitor Use Is Not Associated With Changes in Bone Strength and Structure. Am J Gastroenterol (2016) 1.02
Breast cancer survivorship: a comprehensive review of long-term medical issues and lifestyle recommendations. Perm J (2015) 0.98
Association between Helicobacter pylori Infection and Risk of Osteoporosis in Elderly Taiwanese Women with Upper Gastrointestinal Diseases: A Retrospective Patient Record Review. Gastroenterol Res Pract (2014) 0.96
Use of Acid Suppression Medication is Associated With Risk for C. difficile Infection in Infants and Children: A Population-based Study. Clin Infect Dis (2015) 0.89
Data mining for identifying novel associations and temporal relationships with Charcot foot. J Diabetes Res (2014) 0.85
Use of proton pump inhibitors is associated with fractures in young adults: a population-based study. Osteoporos Int (2015) 0.84
Bone mineral density changes among women initiating proton pump inhibitors or H2 receptor antagonists: a SWAN cohort study. J Bone Miner Res (2015) 0.82
Recent Advances in NSAIDs-Induced Enteropathy Therapeutics: New Options, New Challenges. Gastroenterol Res Pract (2013) 0.81
Esomeprazole use is independently associated with significant reduction of BMD: 1-year prospective comparative safety study of four proton pump inhibitors. J Bone Miner Metab (2015) 0.77
Advances in the evaluation and management of esophageal disease of systemic sclerosis. Curr Rheumatol Rep (2015) 0.77
Cost-effectiveness of chemoprevention with proton pump inhibitors in Barrett's esophagus. Dig Dis Sci (2014) 0.75
Micronutrient deficiencies in patients with chronic atrophic autoimmune gastritis: A review. World J Gastroenterol (2017) 0.75
The Safety of Appropriate Use of Over-the-Counter Proton Pump Inhibitors: An Evidence-Based Review and Delphi Consensus. Drugs (2017) 0.75
The management of gastro-oesophageal reflux disease. Aust Prescr (2016) 0.75
The final word on proton pump inhibitors and osteoporosis? Gastroenterology (2013) 0.75
Proton pump inhibitors do not induce change in bone mineral density in a long-term observational study. Evid Based Med (2012) 0.75
"First Do No Harm": Adverse Events from Pharmaceutical Treatment of Gastroparesis and Dyspepsia. Dig Dis Sci (2017) 0.75
Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA (2006) 9.53
Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA (2005) 6.87
Frailty: emergence and consequences in women aged 65 and older in the Women's Health Initiative Observational Study. J Am Geriatr Soc (2005) 6.73
A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ (2009) 6.21
Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA (2004) 6.06
Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med (1998) 4.24
A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med (1998) 3.96
Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative. Arch Intern Med (2010) 3.53
Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ (2008) 3.31
Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med (2005) 2.98
Proton pump inhibitor use and the antifracture efficacy of alendronate. Arch Intern Med (2011) 2.98
Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors: a prospective cohort study. BMJ (2012) 2.45
Calcium absorption and achlorhydria. N Engl J Med (1985) 2.36
Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int (2006) 2.33
American Gastroenterological Association Institute technical review on the management of gastroesophageal reflux disease. Gastroenterology (2008) 2.23
An evaluation of the importance of gastric acid secretion in the absorption of dietary calcium. J Clin Invest (1984) 1.76
Effect of omeprazole, an inhibitor of H+,K(+)-ATPase, on bone resorption in humans. Calcif Tissue Int (1993) 1.72
Acid-suppressive medications and risk of bone loss and fracture in older adults. Calcif Tissue Int (2008) 1.71
Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology (2009) 1.59
Omeprazole, a specific inhibitor of H+-K+-ATPase, inhibits bone resorption in vitro. Calcif Tissue Int (1986) 1.55
Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. Gastroenterology (2010) 1.55
Impaired gastric acidification negatively affects calcium homeostasis and bone mass. Nat Med (2009) 1.52
Increase in vertebral fracture risk in postmenopausal women using omeprazole. Calcif Tissue Int (2008) 1.26
Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case-control study. Osteoporos Int (2010) 1.17
Calcium and phosphate plasma levels in dialysis patients after dietary Ca-P overload. Role of gastric acid secretion. Nephron (2002) 1.16
Proton pump-inhibiting drugs, calcium homeostasis, and bone health. Nutr Rev (2008) 1.15
Osteopetrosis. Am J Orthop (Belle Mead NJ) (2003) 1.14
The parathyroid glands in experimentally induced hypergastrinemia in the rat. Scand J Gastroenterol (1977) 1.12
Long-term omeprazole treatment suppresses body weight gain and bone mineralization in young male rats. Scand J Gastroenterol (2001) 1.10
Inhibiting gastric acid production does not affect intestinal calcium absorption in young, healthy individuals: a randomized, crossover, controlled clinical trial. J Bone Miner Res (2010) 0.99
Proton pump inhibitors and bone fractures? Am J Gastroenterol (2009) 0.94
Growth of the parathyroid glands in omeprazole-treated chickens. Scand J Gastroenterol (1994) 0.92
Use of proton-pump inhibitors and their associated risks among frail elderly nursing home residents. Scand J Prim Health Care (2010) 0.86
Hip fracture and proton pump inhibitor therapy: position statement. Can J Gastroenterol (2008) 0.83
Another bad break for proton-pump inhibitors? Nat Rev Rheumatol (2009) 0.81
The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab (2010) 13.29
Structure of the novel ternary hydrides Li4Tt2D (Tt=Si and Ge). Acta Crystallogr B (2007) 10.58
2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ (2002) 9.89
Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet (2002) 9.48
Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet (2010) 8.89
Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA (2003) 8.47
2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ (2010) 6.37
Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat Genet (2012) 5.48
In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. Clin Cancer Res (2009) 4.81
Effect of selective serotonin reuptake inhibitors on the risk of fracture. Arch Intern Med (2007) 4.68
DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis. Nat Genet (2006) 4.49
Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma. Nat Genet (2012) 4.07
The Canadian Trial of Carbohydrates in Diabetes (CCD), a 1-y controlled trial of low-glycemic-index dietary carbohydrate in type 2 diabetes: no effect on glycated hemoglobin but reduction in C-reactive protein. Am J Clin Nutr (2008) 3.33
Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ (2008) 3.31
Renal function and risk of hip and vertebral fractures in older women. Arch Intern Med (2007) 3.27
Effect of a low-glycemic index or a high-cereal fiber diet on type 2 diabetes: a randomized trial. JAMA (2008) 3.25
Cytoplasmic domain structures of Kir2.1 and Kir3.1 show sites for modulating gating and rectification. Nat Neurosci (2005) 3.22
Effects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and C-reactive protein. JAMA (2003) 3.03
XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol (2004) 2.93
Synthesis and anticancer activity of thiosemicarbazones. Bioorg Med Chem Lett (2006) 2.78
Effect of soy phytoestrogens on hot flashes in postmenopausal women with breast cancer: a randomized, controlled clinical trial. J Clin Oncol (2002) 2.75
IOM committee members respond to Endocrine Society vitamin D guideline. J Clin Endocrinol Metab (2012) 2.75
Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J Clin Oncol (2006) 2.74
Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res (2015) 2.74
The nonskeletal effects of vitamin D: an Endocrine Society scientific statement. Endocr Rev (2012) 2.71
Relation between fractures and mortality: results from the Canadian Multicentre Osteoporosis Study. CMAJ (2009) 2.64
Validity and reliability of the Block98 food-frequency questionnaire in a sample of Canadian women. Public Health Nutr (2006) 2.63
Calcium-independent and 1,25(OH)2D3-dependent regulation of the renin-angiotensin system in 1alpha-hydroxylase knockout mice. Kidney Int (2008) 2.59
Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw. J Rheumatol (2008) 2.57
Effect of legumes as part of a low glycemic index diet on glycemic control and cardiovascular risk factors in type 2 diabetes mellitus: a randomized controlled trial. Arch Intern Med (2012) 2.54
Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders. Endocrinology (2004) 2.40
Regulated ATP release from astrocytes through lysosome exocytosis. Nat Cell Biol (2007) 2.38
Inducer-stimulated Fas targets activated endothelium for destruction by anti-angiogenic thrombospondin-1 and pigment epithelium-derived factor. Nat Med (2002) 2.34
Polymorphisms in the mannose binding lectin-2 gene and acute respiratory distress syndrome. Crit Care Med (2007) 2.31
Bone microarchitecture assessed by TBS predicts osteoporotic fractures independent of bone density: the Manitoba study. J Bone Miner Res (2011) 2.24
Intensive blood pressure control, falls, and fractures in patients with type 2 diabetes: the ACCORD trial. J Gen Intern Med (2014) 2.20
Using multiple data features improved the validity of osteoporosis case ascertainment from administrative databases. J Clin Epidemiol (2008) 2.19
AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology (2003) 2.17
Recommendations for bone mineral density reporting in Canada. Can Assoc Radiol J (2005) 2.15
Parathyroid hormone-related peptide is required for increased trabecular bone volume in parathyroid hormone-null mice. Endocrinology (2004) 2.14
Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma. Genome Res (2013) 2.12
TARP subtypes differentially and dose-dependently control synaptic AMPA receptor gating. Neuron (2007) 2.07
Fracture risk from psychotropic medications: a population-based analysis. J Clin Psychopharmacol (2008) 2.04
FOXO1A is a candidate for the 13q14 tumor suppressor gene inhibiting androgen receptor signaling in prostate cancer. Cancer Res (2006) 2.03
Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells. Proc Natl Acad Sci U S A (2011) 2.01
The autosomal dominant hypophosphatemic rickets R176Q mutation in fibroblast growth factor 23 resists proteolytic cleavage and enhances in vivo biological potency. J Biol Chem (2003) 1.99
Arrowsmith two-node search interface: a tutorial on finding meaningful links between two disparate sets of articles in MEDLINE. Comput Methods Programs Biomed (2009) 1.96
Inhibition of lymphocyte trafficking shields the brain against deleterious neuroinflammation after stroke. Brain (2011) 1.95
VEGF polymorphisms and survival in early-stage non-small-cell lung cancer. J Clin Oncol (2008) 1.94
Altered ovarian function affects skeletal homeostasis independent of the action of follicle-stimulating hormone. Endocrinology (2007) 1.94
Sympathetic innervation of the anterior left ventricular wall by the right and left stellate ganglia. Heart Rhythm (2012) 1.93
The 2002 Canadian bone densitometry recommendations: take-home messages. CMAJ (2002) 1.92
Inactivation of the 25-hydroxyvitamin D 1alpha-hydroxylase and vitamin D receptor demonstrates independent and interdependent effects of calcium and vitamin D on skeletal and mineral homeostasis. J Biol Chem (2004) 1.91
Bisphosphonate associated osteonecrosis of the jaw. J Rheumatol (2009) 1.90
Up-regulation of Wnt-1 and beta-catenin production in patients with advanced metastatic prostate carcinoma: potential pathogenetic and prognostic implications. Cancer (2004) 1.90
Osteoblast-derived PTHrP is a potent endogenous bone anabolic agent that modifies the therapeutic efficacy of administered PTH 1-34. J Clin Invest (2005) 1.88
Effect of wheat bran on glycemic control and risk factors for cardiovascular disease in type 2 diabetes. Diabetes Care (2002) 1.88
Menstrual and reproductive risk factors and risk for gastric adenocarcinoma in women: findings from the canadian national enhanced cancer surveillance system. Ann Epidemiol (2006) 1.88
Trabecular bone score: a noninvasive analytical method based upon the DXA image. J Bone Miner Res (2014) 1.86
Bone turnover markers in the management of postmenopausal osteoporosis. Clin Biochem (2009) 1.85
Impact of DNA ligase IV on nonhomologous end joining pathways during class switch recombination in human cells. J Exp Med (2005) 1.84
FRAX underestimates fracture risk in patients with diabetes. J Bone Miner Res (2012) 1.82
Low bone mineral density and fracture burden in postmenopausal women. CMAJ (2007) 1.81
Direct comparison of a dietary portfolio of cholesterol-lowering foods with a statin in hypercholesterolemic participants. Am J Clin Nutr (2005) 1.80
The 2011 Dietary Reference Intakes for Calcium and Vitamin D: what dietetics practitioners need to know. J Am Diet Assoc (2011) 1.80
Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. Am J Med (2012) 1.80
Implication of snoRNA U50 in human breast cancer. J Genet Genomics (2009) 1.80
Autosomal dominant pseudohypoparathyroidism type Ib is associated with a heterozygous microdeletion that likely disrupts a putative imprinting control element of GNAS. J Clin Invest (2003) 1.77
Parathyroid hormone is essential for normal fetal bone formation. J Clin Invest (2002) 1.76
The effect of proton pump inhibitors on fracture risk: report from the Canadian Multicenter Osteoporosis Study. Osteoporos Int (2012) 1.76
Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation. Cancer (2006) 1.75
Calcitonin plays a critical role in regulating skeletal mineral metabolism during lactation. Endocrinology (2006) 1.74
Parathyroid hormone for the treatment of osteoporosis: a systematic review. CMAJ (2006) 1.74
Effective initiation of osteoporosis diagnosis and treatment for patients with a fragility fracture in an orthopaedic environment. J Bone Joint Surg Am (2006) 1.72
Genomic and proteomic analyses of the fungus Arthrobotrys oligospora provide insights into nematode-trap formation. PLoS Pathog (2011) 1.72
Inhibitor kappaB-alpha haplotype GTC is associated with susceptibility to acute respiratory distress syndrome in Caucasians. Crit Care Med (2007) 1.71
Effect of a low glycaemic index diet on blood glucose in women with gestational hyperglycaemia. Diabetes Res Clin Pract (2010) 1.71
Vitamin D insufficiency in North America. J Nutr (2005) 1.70
Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab. Clin Cancer Res (2009) 1.70
Mitomycin C-polyethylene glycol controlled-release film inhibits collagen secretion and induces apoptosis of fibroblasts in the early wound of a postlaminectomy rat model. Spine J (2010) 1.69
P21-activated kinase 1 (PAK1) as a therapeutic target in BRAF wild-type melanoma. J Natl Cancer Inst (2013) 1.68
Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis. J Endocrinol (2004) 1.67
Macroscopic, neat, single-walled carbon nanotube fibers. Science (2004) 1.67
Identification of a novel small-molecule inhibitor of the hypoxia-inducible factor 1 pathway. Cancer Res (2005) 1.67
Promoter hypermethylation-mediated down-regulation of LATS1 and LATS2 in human astrocytoma. Neurosci Res (2006) 1.67
Risedronate prevents new vertebral fractures in postmenopausal women at high risk. J Clin Endocrinol Metab (2003) 1.65
Rotating shift work and risk of prostate cancer. Epidemiology (2007) 1.64